Results 141 to 150 of about 379,515 (350)

Long‐term quality of life in patients with bladder cancer following radical cystectomy

BJU International, Volume 135, Issue 4, Page 675-683, April 2025.
Objectives To investigate changes in quality of life (QoL) up to 8 years after radical cystectomy (RC) and compare QoL after RC with a gender‐ and age‐matched Dutch normative population. Furthermore, we aimed to identify patient characteristics associated with QoL and QoL trajectories after RC.
Emine Akdemir, Martijn M. Stuiver, Maaike W. van de Kamp, Jolanda Bloos ‐ van der Hulst, Laura S. Mertens, Kees Hendricksen, Wim H. van Harten, Anne M. May, Maike G. Sweegers   +8 more
wiley   +1 more source

Computed tomography and magnetic resonance findings of fat-poor angiomyolipomas [PDF]

, 2017
Bauman, Tyler M, Figenshau, Robert Sherburne, Knight, B. Alexander, Mobley, Jonathan M, Park, Alyssa M, Potretzke, Aaron M, Potretzke, Theodora A, Siegel, Cary Lynn   +7 more
core   +2 more sources

Recommendation on the use of protective eyewear in endourological laser procedures

BJU International, Volume 135, Issue 4, Page 577-581, April 2025.
Objectives This work examines the current evidence available regarding the risks of eye injury in endourology laser environments with the aim of providing a consensus recommendation on the appropriate use of protective eyewear. Methods A working group was set up consisting of urological surgeons and laser protection advisors.
Tom Lister, Stan Batchelor, Mike Regan, Jason Britton, Hari Ratan, Feras Al‐Jaafari, Jake Patterson, British Medical Laser Association and the British Association of Urological Surgeons Endourology Section   +7 more
wiley   +1 more source

Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980 [PDF]

, 2017
Background After a peak in the late 1980s, cancer mortality in Europe has declined by ∼10% in both sexes up to the early 2000s. We provide an up-to-date picture of patterns and trends in mortality from major cancers in Europe.
Bertuccio, P., Bosetti, C., Chatenoud, L., La Vecchia, C., Levi, F., Malvezzi, M., Negri, E.   +6 more
core  

Long‐term outcomes of a cascading salvage strategy for high‐risk non‐muscle‐invasive bladder cancer

BJU International, EarlyView.
Objective To report long‐term oncological outcomes of patients with high‐risk non‐muscle‐invasive bladder cancer (HR‐NMIBC) undergoing bladder‐sparing therapy (BST) after bacillus Calmette–Guérin (BCG) failure. Patients and Methods We retrospectively reviewed patients with HR‐NMIBC treated from 2000 to 2025 with intravesical therapies after BCG failure,
Ian M. McElree, Ryan L. Steinberg, Helen Y. Hougen, Sarah L. Mott, Vignesh T. Packiam, Michael A. O'Donnell   +5 more
wiley   +1 more source

What is new in Genitourinary Pathology? Recent developments and highlights of the new 2016 World Health Organization classification of tumors of the urinary system and male genital organs [PDF]

, 2016
Daniel Abensur Athanazio, Kiril Trpkov
core   +1 more source

Association Between Twelve Polymorphisms in Five X-ray Repair Cross-complementing Genes and the Risk of Urological Neoplasms: A Systematic Review and Meta-Analysis

, 2017
Meng Zhang, Wanzhen Li, Zongyao Hao, Jun Zhou, Li Zhang, Chang Yin Liang   +5 more
openalex   +1 more source

Drug‐releasing intravesical floating technology for sequential gemcitabine and docetaxel in non‐muscle‐invasive bladder cancer

BJU International, EarlyView.
Objectives To develop a drug‐releasing intravesical floating technology (DRIFT) device for controlled sequential delivery of gemcitabine and docetaxel (Gem/Doce) to optimise the treatment of non‐muscle‐invasive bladder cancer (NMIBC) while enabling patient mobility and self‐removal, as sequential intravesical Gem/Doce has been increasingly utilised but
Ashley C. Rhodes, Kaitlyn A. McClintic, Emily Witt, Ikenna Nwosu, Kyle R. Balk, Colin Reis, Ian C. Sutton, Jianling Bi, Melinda Z. Fu, Michael A. O’Donnell, Vignesh T. Packiam, James D. Byrne   +11 more
wiley   +1 more source

Prostate zonal impact of 5α‐reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer

BJU International, EarlyView.
Objectives To assess the impact of 5α‐reductase inhibitors (5‐ARIs) on multiparametric magnetic resonance imaging (mpMRI) features of Prostate Imaging‐Reporting and Data System (PI‐RADS) lesions and their influence on the detection of clinically significant prostate cancer (csPCa), with a focus on differences between prostate zones.
Arighno Das, Marcelo Bigarella, Krista Brackman, Glenn O. Allen, Soroush Rais‐Bahrami, Kayla Bahr, Emily Schmitt, Andrew M. Fang, Hunter Boudreau, Christopher P. Filson, Melina Pectasides, Giuseppe V. Toia, David F. Jarrard   +12 more
wiley   +1 more source

Selective ablating urologic cancers with cold atmospheric plasma [PDF]

, 2017
info:eu-repo/semantics ...
Abrantes, AM, Almeida-Ferreira, C, Botelho, MF, Caramelo, F, Figueiredo, A, Laranjo, M, Marques, I, Neves, R, Silva-Teixeira, R, Tavares da Silva, E   +9 more
core